On Aug. 25, 2021, Anixa Biosciences announced that a genomic variant analysis indicateed that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2. Anixa’s program in collaboration with European partner MolGenie, focuses on identifying novel, small molecule inhibitors of Mpro, the main protease of the virus.